Adams Diversified Equity Fund Inc. continued to hold its stake in Edwards Lifesciences Corp.
Cohen Lawrence B decreased Edwards Lifesciences Corp (EW) stake by 13.99% reported in 2017Q2 SEC filing. The Partner Investment Management Lp holds 13,938 shares with $1.65 million value, up from 11,015 last quarter.
A number of other institutional investors have also recently bought and sold shares of the business. Amalgamated Bank now controls 25,224 shares worth $2,757,000. TNB Financial acquired a new position in shares of Edwards Lifesciences Corporation during the second quarter worth about $204,000. In the last ninety days, insiders sold 138,580 shares of company stock worth $15,039,844. Jennison Associates LLC grew its holdings in Edwards Lifesciences Corporation by 6.2% during the third quarter. Checchi Capital Advisers LLC increased its stake in Edwards Lifesciences Corp.by 3.9% in the second quarter. The stock declined 0.36% or $0.37 reaching $103.48 per share. Finally, Norinchukin Bank The increased its stake in Edwards Lifesciences Corp.by 0.8% in the second quarter. Scout Investments Inc. now owns 229,855 shares of the medical research company's stock worth $25,125,000 after acquiring an additional 2,127 shares during the period. Institutional investors and hedge funds own 82.69% of the company's stock. The stock rose 0.21% or $0.11 reaching $52.18 per share. The stock has a market cap of $22,200.00, a price-to-earnings ratio of 28.77, a price-to-earnings-growth ratio of 1.86 and a beta of 0.46. The stock's 52-week range is $81.12 to $121.45, and its 3-month range is $100.20 to $115.94. Edwards Lifesciences Corp had 84 analyst reports since July 30, 2015 according to SRatingsIntel.
Edwards Lifesciences Corporation (EW) opened at $102.72 on Friday. As of the latest earnings report the EPS was $3.44 with 211.62M shares presently outstanding. The firm had revenue of $821.50 million for the quarter, compared to analyst estimates of $833.85 million. During the same quarter a year ago, the business posted $0.54 earnings per share. The company's revenue was up 11.1% compared to the same quarter a year ago. During the same period in the prior year, the firm earned $0.68 EPS. equities research analysts expect that Edwards Lifesciences Corporation will post 3.75 EPS for the current fiscal year. Maintains Position in Edwards Lifesciences Corp. If you are viewing this article on another website, it was stolen and reposted in violation of United States and worldwide copyright & trademark law.
More notable recent Edwards Lifesciences Corp (NYSE:EW) news were published by: Seekingalpha.com which released: "Edwards Lifesciences (EW) CEO Mike Mussallem on Q3 2017 Results - Earnings ..." on October 25, 2017, also Cnbc.com with their article: "Cramer's lightning round: I'm a buyer of Edwards Lifesciences despite the ..." published on October 31, 2017, Prnewswire.com published: "Edwards SAPIEN 3 Transcatheter Valve Demonstrates Significant Cost Savings ..." on October 31, 2017.
Several brokerages have issued reports on EW.
The average Wall Street analyst rating for Edwards Lifesciences Corporation is Strong Buy, according to the average of 15 analyst scores. Canaccord Genuity reaffirmed a "buy" rating and issued a $155.00 price objective on shares of Edwards Lifesciences Corporation in a research report on Sunday, October 8th. Finally, Zacks Investment Research raised shares of Edwards Lifesciences Corporation from a "hold" rating to a "buy" rating and set a $130.00 price objective for the company in a research report on Tuesday, July 18th. RBC Capital Markets maintained it with "Buy" rating and $130.0 target in Monday, October 2 report.
Morgan Stanley lowered the price target on October 26 cutting the projection from $133.00 to $120.00 with a rating of "Overweight". Seven investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. On Tuesday, May 30 the stock rating was maintained by RBC Capital Markets with "Buy". The stock saw a fall in short interest of -4.22% between October 13, 2017 and October 31, 2017. The stock was sold at an average price of $120.04, for a total value of $1,638,546.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The firm has "Outperform" rating by William Blair given on Monday, August 28. The shares were sold at an average price of $111.81, for a total transaction of $2,119,917.60. The disclosure for this sale can be found here. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. The Firm offers a range of services to its customers, including design and development, engineering services, supply chain management, new product introduction, component sourcing, electronics manufacturing, assembly and test, complex mechanical assembly, systems integration, precision machining, order fulfillment, logistics and after-market fix and return services.